Exploiting drug repositioning and the brain microenvironment to treat brain metastases.

about

Exploiting drug repositioning and the brain microenvironment to treat brain metastases.

Item

http://www.wikidata.org/entity/Q42944473

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Exploiting drug repositioning and the brain microenvironment to treat brain metastases.

@en

Exploiting drug repositioning and the brain microenvironment to treat brain metastases.

@nl

type

Item

label

Exploiting drug repositioning and the brain microenvironment to treat brain metastases.

@en

Exploiting drug repositioning and the brain microenvironment to treat brain metastases.

@nl

prefLabel

Exploiting drug repositioning and the brain microenvironment to treat brain metastases.

@en

Exploiting drug repositioning and the brain microenvironment to treat brain metastases.

@nl

P1476

Exploiting drug repositioning and the brain microenvironment to treat brain metastases.

@en

P2093

Robert S Kerbel

http://www.w3.org/2001/XMLSchema#string

P2860

The endothelin axis: emerging role in cancer

Endothelin B receptor, a new target in cancer immune therapy.

Role of the endothelin axis in astrocyte- and endothelial cell-mediated chemoprotection of cancer cells.

Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.

Continuous local delivery of interferon-β stabilizes tumor vasculature in an orthotopic glioblastoma xenograft resection model

Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice

Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.

Brain metastases: the HER2 paradigm.

Endothelin receptor antagonists in cancer therapy.

P304

459-461

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1093/NEUONC/NOV327

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26833406

http://www.w3.org/2001/XMLSchema#string

P932

4799688

http://www.w3.org/2001/XMLSchema#string